- Abstract
- Core Tip
- Full Article (PDF)
- Full Article with Cover (PDF)
- Full Article (XML)
- Full Article (HTML)
- Audio
- PubMed Central
- PubMed
- CrossRef
- Google Scholar
- Similar Articles (245)
- Timeline of Article Publication (1)
- Authors Evaluation (1)
- Article Quality Tracking (2)
- Reference Citation Analysis (1)
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5526)
All Articles published online
|
Publishing Process of This Article
|
Jul 7, 2023 (publication date) through Apr 6, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Pal SC, Méndez-Sánchez N. Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis. World J Gastroenterol 2023; 29(25): 3999-4008 [PMID: 37476582 DOI: 10.3748/wjg.v29.i25.3999] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v29/i25/3999.htm |
| Number | Citing Articles |
| 1 |
Anton Bermont, Daniel L. Cohen, Vered Richter, Rivka Hadar, Joseph Tam, Ayelet Wandel, Solli Brawer, Omer Grundman, Haim Shirin. FucoVital® inhibits fatty acid accumulation in liver cells in vitro and reduces triglycerides levels in patients with NAFLD. PharmaNutrition 2025; 31: 100429 doi: 10.1016/j.phanu.2025.100429
|
| 2 |
Jorge Arnold, Francisco Idalsoaga, Luis Antonio Díaz, Daniel Cabrera, Francisco Barrera, Juan Pablo Arab, Marco Arrese. Emerging Drug Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Glimpse into the Horizon. Current Hepatology Reports 2024; 23(1): 204 doi: 10.1007/s11901-023-00629-0
|
| 3 |
Haixiang Zheng, Leonardo Antonio Sechi, Eliano Pio Navarese, Gavino Casu, Gianpaolo Vidili. Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review. Cardiovascular Diabetology 2024; 23(1) doi: 10.1186/s12933-024-02434-5
|
| 4 |
Lijuan Liu, Weiming Sun, Xulei Tang, Donghu Zhen, Conghui Guan, Songbo Fu, Jinjin Liu. Chiglitazar attenuates high-fat diet-induced nonalcoholic fatty liver disease by modulating multiple pathways in mice. Molecular and Cellular Endocrinology 2024; 593: 112337 doi: 10.1016/j.mce.2024.112337
|
| 5 |
Qian Xue, Hongju Chen. Association of blood manganese levels with non-alcoholic fatty liver disease in NHANES 2017–2020: A retrospective cross-sectional study. Metabolism Open 2025; 26: 100358 doi: 10.1016/j.metop.2025.100358
|
| 6 |
Supriyo Ghosh, Amlan Jyoti Ghosh, Rejuan Islam, Sagar Sarkar, Tilak Saha, Ahmed Khalafallah Sadeq Rashwan. Lactobacillus plantarum KAD protects against high-fat diet-induced hepatic complications in Swiss albino mice: Role of inflammation and gut integrity. PLOS ONE 2024; 19(11): e0313548 doi: 10.1371/journal.pone.0313548
|
| 7 |
Raissa Bulaty Tauil, Paula Takano Golono, Enzo Pereira de Lima, Ricardo de Alvares Goulart, Elen Landgraf Guiguer, Marcelo Dib Bechara, Claudia C. T. Nicolau, José Luiz Yanaguizawa Junior, Adriana M. R. Fiorini, Nahum Méndez-Sánchez, Ludovico Abenavoli, Rosa Direito, Vitor Engrácia Valente, Lucas Fornari Laurindo, Sandra Maria Barbalho. Metabolic-Associated Fatty Liver Disease: The Influence of Oxidative Stress, Inflammation, Mitochondrial Dysfunctions, and the Role of Polyphenols. Pharmaceuticals 2024; 17(10): 1354 doi: 10.3390/ph17101354
|
| 8 |
Yingyong Ou, Zihan Qin, Pinze Wang, Fan Zou. Serum uric acid to high-density lipoprotein cholesterol ratio predicts all-cause mortality in adults with metabolic dysfunction associated steatotic liver disease. Scientific Reports 2025; 15(1) doi: 10.1038/s41598-025-94651-5
|
| 9 |
Mohammadjavad Sotoudeheian. Agile 3+ and Metabolic Dysfunction-Associated Fatty Liver Disease:
Detecting Advanced Fibrosis based on Reported Liver Stiffness
Measurement in FibroScan and Laboratory Findings. The International Journal of Gastroenterology and Hepatology Diseases 2024; 3 doi: 10.2174/0126662906302851240604042954
|
| 10 |
Vlad Alexandru Ionescu, Gina Gheorghe, Nicolae Bacalbasa, Camelia Cristina Diaconu. Metabolic Dysfunction-Associated Steatotic Liver Disease: Pathogenetic Links to Cardiovascular Risk. Biomolecules 2025; 15(2): 163 doi: 10.3390/biom15020163
|
| 11 |
Júlia Pauli De Cól, Enzo Pereira de Lima, Fernanda Moris Pompeu, Adriano Cressoni Araújo, Ricardo de Alvares Goulart, Marcelo Dib Bechara, Lucas Fornari Laurindo, Nahum Méndez-Sánchez, Sandra Maria Barbalho. Underlying Mechanisms behind the Brain–Gut–Liver Axis and Metabolic-Associated Fatty Liver Disease (MAFLD): An Update. International Journal of Molecular Sciences 2024; 25(7): 3694 doi: 10.3390/ijms25073694
|
| 12 |
Xiuxian Huang, Zhengming Li, Zhenwei Zhai, Qiu Wang, Rongyan Wei, Jiacheng Mo, Jianhao Huang, Wensheng Lu. Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and MACCEs in Patients with Diabetic Foot Ulcers: An Ambispective Longitudinal Cohort Study. Diabetes, Metabolic Syndrome and Obesity 2024; : 1119 doi: 10.2147/DMSO.S447897
|
| 13 |
Nikos Adamidis, Petros Papalexis, Sotirios Adamidis. Exploring the Link Between Metabolic Syndrome and Cellulite. Cureus 2024; doi: 10.7759/cureus.63464
|
| 14 |
Hassam Ali, Muhammad Shahzil, Vishali Moond, Maria Shahzad, Abhay Thandavaram, Alina Sehar, Haniya Waseem, Taha Siddiqui, Dushyant Singh Dahiya, Pratik Patel, Hans Tillmann. Non-Pharmacological Approach to Diet and Exercise in Metabolic-Associated Fatty Liver Disease: Bridging the Gap between Research and Clinical Practice. Journal of Personalized Medicine 2024; 14(1): 61 doi: 10.3390/jpm14010061
|
| 15 |
Nouhoum Bouare, Jean Delwaide. Interleukin-mediated therapies in liver diseases and comorbidity effects. World Journal of Hepatology 2024; 16(7): 980-989 doi: 10.4254/wjh.v16.i7.980
|
| 16 |
Nahum Méndez-Sánchez, Mariana M. Ramírez-Mejía, Mohammed Eslam. Metabolic Dysfunction-Associated Steatotic Liver Disease. 2024; : 1 doi: 10.1007/978-981-97-9519-2_1
|
| 17 |
Ashay Shah, Arifa Bakerywala, Riya N. Brahmbhatt, Heena Shaikh, Nidhi Shashikant Bhutak, Renu Singh. The Occurrence of Non-Alcoholic Fatty Liver Disease among Individuals with Diabetes Mellitus: A Comparative Study. Journal of Pharmacy and Bioallied Sciences 2025; doi: 10.4103/jpbs.jpbs_2016_24
|
| 18 |
Anxin Wang, Xue Tian, Qiqi Deng, Manqi Zheng, Xue Xia, Yijun Zhang, Yan Tan, Qian Hua. Longitudinal association of metabolic dysfunction-associated fatty liver disease, serum metabolites, with cognitive function trajectories. npj Metabolic Health and Disease 2025; 3(1) doi: 10.1038/s44324-025-00055-4
|
| 19 |
Marko Mrdjen, Jared Travers, Laura E. Nagy. Reference Module in Biomedical Sciences. 2024; doi: 10.1016/B978-0-323-95488-4.00079-6
|
| 20 |
Shreya C. Pal, Stephany M. Castillo-Castañeda, Luis E. Díaz-Orozco, Mariana M. Ramírez-Mejía, Rita Dorantes-Heredia, Rogelio Alonso-Morales, Mohammed Eslam, Frank Lammert, Nahum Méndez-Sánchez. Molecular Mechanisms Involved in MAFLD in Cholecystectomized Patients: A Cohort Study. Genes 2023; 14(10): 1935 doi: 10.3390/genes14101935
|
| 21 |
Yu Min, Xiaoyuan Wei, Zhigong Wei, Ge Song, Xin Zhao, Yi Lei. Prognostic effect of triglyceride glucose-related parameters on all-cause and cardiovascular mortality in the United States adults with metabolic dysfunction-associated steatotic liver disease. Cardiovascular Diabetology 2024; 23(1) doi: 10.1186/s12933-024-02287-y
|
| 22 |
Mohammadjavad Sotoudeheian. Value of Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) in Assessing Liver Fibrosis in Metabolic Dysfunction-Associated Liver Disease: A Comprehensive Review of its Serum Biomarker Role. Current Protein & Peptide Science 2025; 26(1): 6 doi: 10.2174/0113892037315931240618085529
|
| 23 |
Nahum Méndez-Sánchez, Mariana M. Ramírez-Mejía, Xingshun Qi. Metabolic Dysfunction-Associated Steatotic Liver Disease. 2024; : 7 doi: 10.1007/978-981-97-9519-2_2
|
| 24 |
Milena Vesković, Nikola Šutulović, Dragan Hrnčić, Olivera Stanojlović, Djuro Macut, Dušan Mladenović. The Interconnection between Hepatic Insulin Resistance and Metabolic Dysfunction-Associated Steatotic Liver Disease—The Transition from an Adipocentric to Liver-Centric Approach. Current Issues in Molecular Biology 2023; 45(11): 9084 doi: 10.3390/cimb45110570
|
| 25 |
Yijun Wu, Jingfang Xiong, Gaofeng Chen, Yihui Liu, Changqing Zhao, Zhaolin Zhang, Hong Xu. Oxymatrine relieves non-alcoholic fatty liver disease by promoting sirtuin 1/adenosine 5‘-monophosphate-activated protein kinase pathway and peroxisome proliferator activated receptor alpha-mediated hepatic fatty acid oxidation. European Journal of Pharmacology 2025; 987: 177173 doi: 10.1016/j.ejphar.2024.177173
|
| 26 |
Tomasz Szkudelski, Katarzyna Szkudelska. The Anti-Diabetic Potential of Baicalin: Evidence from Rodent Studies. International Journal of Molecular Sciences 2023; 25(1): 431 doi: 10.3390/ijms25010431
|
| 27 |
Qianzhuo Wang, Yingjuan Zhang, Ruiling Lu, Qingwen Zhao, Yue Gao. The multiple mechanisms and therapeutic significance of rutin in metabolic dysfunction-associated fatty liver disease (MAFLD). Fitoterapia 2024; 178: 106178 doi: 10.1016/j.fitote.2024.106178
|
| 28 |
Hiroki Nishikawa, Soo Ki Kim, Akira Asai. Body Composition in Chronic Liver Disease. International Journal of Molecular Sciences 2024; 25(2): 964 doi: 10.3390/ijms25020964
|
| 29 |
Miranda Sol Orellano, Andrea Scelza-Figueredo, Lucía Lameroli Mauriz, Carolina Sétula, Milagros Argañarás, Catalina Atorrasagasti, Marcelo Javier Perone, Luz Andreone. A dissociated glucocorticoid receptor modulator mitigates glucolipotoxicity in the endocrine pancreas and peripheral tissues: Preclinical data from a mouse model of diet-induced type 2 diabetes. Life Sciences 2025; 362: 123363 doi: 10.1016/j.lfs.2024.123363
|